OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Hinrichs on Unmet Needs with Cellular Therapy in Metastatic Epithelial Cancer

November 23rd 2021

Christian S. Hinrichs, MD, discusses unmet needs with cellular therapies in metastatic epithelial cancer.

Dr. Malhotra on Challenges with Precision Medicine in Advanced Solid Tumors

November 23rd 2021

Jyoti Malhotra, MD, MPH, discusses challenges with precision medicine in advanced solid tumors.

Dr. Bupathi on Considerations for Second-Line Sequencing in RCC

November 23rd 2021

Manojkumar Bupathi, MD, MS, discusses considerations for second-line treatment sequencing in clear cell renal cell carcinoma.

Dr. Palmbos on Remaining Questions in Metastatic Urothelial Carcinoma

November 22nd 2021

Phillip L. Palmbos, MD, PhD, discusses remaining questions in metastatic urothelial carcinoma.

Dr. Lee on Defining Smoldering Multiple Myeloma

November 22nd 2021

Sarah S. Lee, MD, discusses definition criteria for smoldering multiple myeloma.

Dr. Galsky on Developments in SOC Metastatic Urothelial Cancer Treatment

November 22nd 2021

Matthew Galsky, MD, discusses key developments in the standard-of-care treatment of patients with metastatic or advanced urothelial cancer.

Dr. Cohen on the Importance of Obtaining an Adequate Tissue Sample in GI Malignancies

November 22nd 2021

Steven J. Cohen, MD, discusses the importance of obtaining an adequate tissue sample for molecular testing in gastrointestinal cancers.

Dr. Ganesan on Leveraging Precision Medicine to Improve Cancer Care

November 22nd 2021

Shridar Ganesan, MD, PhD, discusses improvements in precision medicine and the need to enroll patients with different molecular subtypes into specifically designed clinical trials.

Dr. Hochster on Treatment Considerations for HER2+ Gastric Cancer

November 22nd 2021

Howard S. Hochster, MD, FACP, discusses treatment considerations for patients with HER2-positive gastric cancer.

Dr. Wilky on the Diagnosis and Management of Desmoid Tumors

November 19th 2021

Breelyn Wilky, MD, discusses the diagnosis and management of desmoid tumors.

Dr. Falkson on Opportunities for De-Escalating Therapy in HER2+ Breast Cancer

November 19th 2021

Carla Falkson, MBChB, MMed, MD, discusses opportunities for de-escalating therapy in patients with HER2-positive breast cancer.

Dr. Choueiri on the FDA Approval of Adjuvant Pembrolizumab in RCC

November 19th 2021

Toni K. Choueiri, MD, discusses the FDA approval of adjuvant pembrolizumab in renal cell carcinoma.

Dr. Moutafi on the Results of a Study Evaluating Biomarkers of Resistance in NSCLC

November 19th 2021

Myrto Moutafi, MD, MSc, discusses the results of a study evaluating biomarkers of resistance in non–small cell lung cancer.

Dr. Nebhan on the Efficacy of Checkpoint Inhibitors in Older Patients With Cancer

November 19th 2021

Caroline Nebhan, MD, PhD, discusses the efficacy of checkpoint inhibitors in older patients with cancer.

Dr. Mesa on Navigating the Expanding Paradigm of JAK Inhibitors in MPNs

November 19th 2021

Ruben A. Mesa, MD, discusses strategies for navigating the expanding paradigm of JAK inhibitors in myeloproliferative neoplasms.

Dr. Wildiers on the Final Results of the AIPAC Trial in HR+/HER2- Metastatic Breast Cancer

November 19th 2021

Hans Wildiers, MD, medical oncologist, Department of Medical Oncology, full professor, Faculty of Medicine, member, Laboratory of Experimental Oncology, University Hospital Leuven, Leuven, Belgium, discusses the final results of the phase 2b AIPAC trial (NCT02614833) in hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.

Dr. Cheng on Advances With Immunotherapy-Based Combinations in Oncology

November 19th 2021

Jonathan D. Cheng, MD, discusses advances with immunotherapy-based combinations in oncology.

Dr. Stefanovic on the Emergence of Umbralisib in MZL and Follicular Lymphoma

November 18th 2021

Alexandra Stefanovic, MD, discusses the emergence of umbralisib in marginal zone lymphoma and follicular lymphoma.

Dr. Ramnaraign on Current Treatment Guidelines for First-Line Metastatic RCC

November 18th 2021

Brian Ramnaraign, MD, discusses current first-line treatment guidelines for patients with metastatic renal cell carcinoma.

Dr. El-Rayes on the Efficacy of Tidutamab in Advanced NETs

November 18th 2021

Bassel El-Rayes, MD, discusses the efficacy of tidutamab in advanced neuroendocrine tumors.